The Pharmaceuticals and Medical Devices Agency (PMDA) puts great emphasis on communication with stakeholders, including public and industries. Since April 2020, Chief Executive Dr. FUJIWARA has been releasing various statements in English to better communicate PMDA’s positions on recent issues around global public health. Please open each file below to access individual statement. The PMDA continues to deliver information of public interest and exchange opinions with stakeholders to protect and improve the health of people by cooperating with other regulatory authorities.
- No.17 Further cooperation on medical products regulation with Thailand - Five-Year Joint Action Plan on Japan-Thailand Strategic Economic Partnership - [96.66KB] (November 18, 2022)
- No.16 For patients, with patients -PMDA is further endeavoring “Patients First” in 2022 - [251.72KB] (January 4, 2022)
- No.15 Towards “Drug and Health Week” - Consideration with relief services for adverse health effects - [256.82KB] (October 26, 2021)
- No.14 PMDA facing towards “Drug-induced Suffering”- Exhibition Room for Remembrance of History of Drug-induced Suffering in PMDA - [295.26KB] (August 24, 2021)
- No.13 For more and closer communication with Patients- PMDA’s efforts for patient satisfaction - [263.95KB] (August 5, 2021)
- No.12 Toward the Earlier Marketing of Innovative Medical Devices [402.67KB] (May 24, 2021)
- No.11 Utilization of Real World Data - PMDA’s approaches - [119.88KB] (March 23, 2021)
- No.10 Special Approval for Emergency on First COVID-19 Vaccine in Japan [252.14KB] (February 16,2021)
- No.9 To Boost Japan-first Medical Product Approvals ~ PMDA Now Looks at Next Steps ~ [278.53KB] (November 24, 2020)
- No.8 PMDA Reveals Principles on Evaluation of COVID-19 Vaccines [254.95KB] (October 12, 2020)
- No.7 PMDA to Offer Free Scientific Advice for COVID-19 Vaccines Development [248.55KB] (October 6, 2020)
- No.6 For Your Access to Japanese Clinical Trial/Clinical Research Information [171.26KB] (June 4, 2020)
- No.5 First Approval of Antigen Test for COVID-19 [168.84KB] (May 13, 2020)
- No.4 Special Approval for Emergency on Remdesivir for COVID-19 [175.51KB] (May 8, 2020)
- No.3 Four IVDs Approvals for COVID-19 and Response to the Increased Ventilator Demand [201.91KB] (April 21, 2020)
- No.2 PMDA Takes Further Steps to Speed up Clinical Development of COVID-19 Products [182.57KB] (April 10, 2020)
- No.1 PMDA pledge to tackle COVID-19 Pandemic [70.77KB] (March 31, 2020)